SPC293
Fostamatíníb eða lyfjafræðilega viðunandi salt af fostamatíníb, eða hýdrat, lausnarsamband eða N-oxíð af fostamatíníb eða lyfjafræðilega viðunandi saltinu af fostamatíníb, sérstaklega fostamatíníbdínatríum, mögulega á formi hýdrats
Status:
AfskrifuðApplication date:
8.5.2020Application published:
15.5.2020Grant published:
15.4.2021
Max expiry date:
18.1.2031Medicine name:
TavlesseMedicine for children:
No
Timeline
Today
8.5.2020Application
15.5.2020Publication
15.4.2021Registration
18.1.2031Expires
Marketing license
IS authorization number:
EU/1/19/1405/001-002Date:
15.1.2020
Foreign authorization number:
EU/1/19/1405Date:
9.1.2020
Owner
Name:
Rigel Pharmaceuticals, Inc.Address:
1180 Veterans Boulevard, South San Francisco, CA US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP1856135